A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects
NCT05103878
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy Volunteers
Interventions
DRUG:
BT051 100mg
DRUG:
BT051 300mg
DRUG:
BT051 700mg
DRUG:
BT051 1500mg
DRUG:
BT051 3500mg
DRUG:
Matching Placebo
Sponsor
Bacainn Therapeutics, Inc.